Troxacitabine (Shire Pharmaceuticals).
- Author(s)
- Gerhard Ecker
- Abstract
Shire Pharmaceuticals (formerly BioChem Pharma) is developing troxacitabine (Troxatyl), a novel dioxolane nucleoside analog, as a potential treatment for acute myeloid leukemia (AML), pancreatic cancer and solid tumors. Phase I and II clinical studies in patients with pancreatic cancer and AML are in progress.
- Organisation(s)
- Journal
- Current Opinion in Investigational Drugs
- Volume
- 3
- Pages
- 1533-1538
- No. of pages
- 6
- ISSN
- 1472-4472
- Publication date
- 2002
- Peer reviewed
- Yes
- Austrian Fields of Science 2012
- 3012 Pharmacy, Pharmacology, Toxicology
- Sustainable Development Goals
- SDG 3 - Good Health and Well-being
- Portal url
- https://ucris.univie.ac.at/portal/en/publications/troxacitabine-shire-pharmaceuticals(434a51e3-b912-44d8-88e4-78e1190a504f).html